Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes

项目摘要 该项目利用翻译方法，使用新的分析方法来理解抗药性的出现 治疗结核分枝杆菌(Mtb)的药物，它是结核病(TB)的病原体。耐药结核病 在过去的15年里，全球的发病率上升了80%，死亡率高，疗程长， 以及糟糕的结果。全球耐多药结核病(MDR-TB)平均治愈率为65%，高达11%的 耐多药结核病患者在治疗过程中出现耐药放大现象。而新出现的耐药性是一种 重大挑战往往被发现得太晚了。这项应用将研究两对结核分枝杆菌菌株，这些菌株来自于 药物敏感结核病在基线水平，然后发展为耐药结核病。临床广泛，依从性强 这些患者的数据。将进行耐药机制的功能分析，以更好地了解 正在治疗中的耐药性的发展。

Project Summary This project utilizes translational approaches to use novel assays to understand the emergence of resistance to drugs to treat Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Drug-resistant TB incidence has increased 80% worldwide over the past 15 years with high mortality, prolonged treatment course, and poor outcomes. Global multi-drug resistant TB (MDR-TB) cure rates average 65% and as many as 11% of MDR-TB patients develop amplification of drug-resistance on treatment. While emergent drug-resistance is a major challenge it is often detected too late. This application will study pairs of Mtb strains from patients that had drug-susceptible TB at baseline then developed drug-resistant TB. There is extensive clinical and adherence data for these patients. Functional assays for drug-resistance mechanisms will be done to better understand development of drug-resistance under treatment.